Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Aclidinium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
What Eklira Genuair is The active ingredient of Eklira Genuair is aclidinium bromide, which belongs to a group of medicines called bronchodilators. Bronchodilators relax airways and help keep bronchioles open. Eklira Genuair is a dry powder inhaler that uses your breath to deliver the medicine directly into your lungs. This makes it easier for chronic obstructive pulmonary disease (COPD) patients to breathe. What Eklira Genuair is used for Eklira Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, longterm lung disease characterised by breathing difficulties. Regular use of Eklira Genuair can help you when you have ongoing shortness of breath related to your disease to help you minimise the effects of the disease on your everyday life and reduce the number of flare-ups (the worsening of your COPD symptoms for several days). 2.
e Eklira Genuair
Do not use Eklira Genuair
Dry mouth, which has been observed with medicines like Eklira Genuair, may after using your medicine for a long time, be associated with tooth decay. Therefore, please remember to pay attention to oral hygiene. Stop taking Eklira Genuair and seek medical help immediately: if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. These may be signs of a condition called bronchospasm. Children and adolescents Eklira Genuair is not for use in children or adolescents below 18 years of age. Other medicines and Eklira Genuair Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Inform your doctor if you have been or are using similar medicines for breathing problems, such as medicines containing tiotropium, ipratropium. Ask your doctor or pharmacist if you are not sure. The use of Eklira Genuair with these medicines is not recommended. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use Eklira Genuair if you are pregnant or are breast-feeding unless your doctor tells you so. Driving and using machines Eklira Genuair may have minor influence on the ability to drive and use machines. This medicine may cause headache, dizziness or blurred vision. If you are affected by any of these side effects do not drive or use machinery until the headache has cleared, the feeling of dizziness has passed and your vision has returned to normal. Eklira Genuair contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 3.
How to use Eklira Genuair
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one inhalation twice a day in the morning and evening. The effects of Eklira Genuair last for 12 hours; therefore, you should try to use your Eklira Genuair inhaler at the same time every morning and evening. This ensures that there is always enough medicine in your body to help you breathe more easily throughout the day and night. It will also help you to remember to use it. The recommended dose can be used for elderly patients and for patients with kidney or liver problems. No dose adjustments are necessary. COPD is a long-term disease; therefore, it is recommended that Eklira Genuair is used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced. Route of administration The medicine is for inhalation use. Refer to Instructions for Use for instructions on how to use the Genuair inhaler. If you are not sure of
Eklira Genuair, contact your doctor or pharmacist.
You can use Eklira Genuair any time before or after food or drink. If you use more Eklira Genuair than you should If you think you may have used more Eklira Genuair than you should, contact your doctor or pharmacist. If you forget to use Eklira Genuair If you forget a dose of Eklira Genuair, inhale the dose as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. If you stop using Eklira Genuair This medicine is for long-term use. If you want to stop treatment, first talk to your doctor, as your symptoms may worsen. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions may rarely occur (may affect up to 1 in 1,000 people). Stop using the medicine and contact your doctor immediately if you develop swelling of your face, throat, lips or tongue (with or without difficulty breathing or swallowing), dizziness or fainting, faster heart rate or if you get raised severely itchy bumps on your skin (hives) as these may be symptoms of an allergic reaction. The following side effects may occur whilst using Eklira Genuair: Common: may affect up to 1 in 10 people
5.
Eklira Genuair
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the inhaler label and carton after "EXP". The expiry date refers to the last day that month. Keep the inhaler inside the pouch until the administration period starts. To be used within 90 days of opening the pouch. Do not use the Eklira Genuair if you notice that the pack is damaged or shows signs of tampering. After you have taken the last dose, the inhaler has to be disposed of. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Eklira Genuair contains The active substance is aclidinium bromide. Each delivered dose contains 375 micrograms aclidinium bromide equivalent to 322 micrograms of aclidinium. The other ingredient is lactose monohydrate (refer to Section 2 "Eklira Genuair contains lactose"). What Eklira Genuair looks like and contents of the pack Eklira Genuair is a white or almost white powder. The Genuair inhaler device is white coloured with an integral dose indicator and a green dosage button. The mouthpiece is covered with a removable green protective cap. It is supplied in a plastic pouch. Pack sizes supplied: Carton containing 1 inhaler with 30 doses. Carton containing 1 inhaler with 60 doses. Carton containing 3 inhalers each with 60 doses. Not all pack sizes may be marketed. Marketing Authorisation Holder Azurity Pharmaceuticals Ireland Ltd. The Observatory 7-11 Sir John Rogerson's Quay Dublin 2, D02 VC42 Ireland Manufacturer Industrias Farmacéuticas Almirall, S.A. Ctra. de Martorell 41-61 08740 Sant Andreu de la Barca, Barcelona Spain This leaflet was last revised in July 2026.
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 08004334029 (UK only) Please be ready to give the following information: Product name Eklira Genuair 322 micrograms inhalation powder
Reference number PL 60277/0004
This is a service provided by the Royal National Institute of the Blind. Instructions for Use This section contains information on how to use your Genuair inhaler. It is important that you read this information as the Genuair may work differently from inhalers you have used previously. If you have any questions about how to use your inhaler, please ask your doctor, pharmacist or nurse for assistance. The Instructions for Use is divided into the following sections:
Control window Green = inhaler ready to use
Dose indicator
Protective Cap
Green button
Control window Red = confirms correct inhalation Mouthpiece
Figure A
Before use: a) Before first use, tear open the sealed bag and remove the inhaler. Throw away the bag. b) Do not press the green button until you are ready to take a dose. c) Pull off the cap by lightly squeezing the arrows marked on each side (Figure B).
Squeeze here and pull
Figure B STEP 1: Prepare your dose 1.1 Look in the opening of the mouthpiece and make sure nothing is blocking it (Figure C). 1.2 Look at the control window (should be red, Figure C). RED
Check mouthpiece opening Figure C 1.3 Hold the inhaler horizontally with the mouthpiece facing you and the green button on top (Figure D).
Figure D 1.4 Press the green button all the way down to load your dose (Figure E). When you press the button all the way down, the control window changes from red to green.
Make sure the green button is on top. Do not tilt. 1.5 Release the green button (Figure F). Make sure you release the button so the inhaler can work correctly.
Figure E
Figure F
Stop and Check: 1.6 Make sure the control window is now green (Figure G). Your medicine is ready to be inhaled. Go to 'STEP 2: Inhale your medicine'. GREEN
Figure G What to do if the control window is still red after pressing the button (Figure H).
Figure H The dose is not prepared. Go back to 'STEP 1 Prepare your dose' and repeat steps 1.1 to 1.6.
STEP 2: Inhale your medicine Read steps 2.1 to 2.7 fully before use. Do not tilt. 2.1 Hold the inhaler away from your mouth, and breathe out completely. Never breathe out into the inhaler (Figure I).
Figure I 2.2 Hold your head upright, put the mouthpiece between your lips, and close your lips tightly around it (Figure J). Do not hold the green button down while inhaling.
Figure J 2.3 Take a strong, deep breath through your mouth. Keep breathing in for as long as possible. A 'click' will let you know that you are inhaling correctly. Keep breathing in as long as possible after you hear the 'click'. Some patients may not hear the 'click'. Use the control window to ensure you have inhaled correctly. 2.4 Take the inhaler out of your mouth. 2.5 Hold your breath for as long as possible. 2.6 Slowly breathe out away from the inhaler. Some patients may experience a grainy sensation in their mouth, or a slightly sweet or bitter taste. Do not take an extra dose even if you do not taste or feel anything after inhaling. Stop and Check: 2.7 Make sure the control window is now red (Figure K). This means you have inhaled your medicine correctly.
RED
Figure K What to do if the control window is still green after inhalation (Figure L).
Figure L This means you have not inhaled your medicine correctly. Go back to 'STEP 2 Inhale your medicine' and repeat steps 2.1 to 2.7. If the control window still does not change to red, you may have forgotten to release the green button before inhaling, or you may not have inhaled strongly enough. If this happens, try again. Make sure you have released the green button, and you have breathed out completely. Then take a strong, deep breath through the mouthpiece. Please contact your doctor if the control window is still green after repeated attempts. Push the protective cap back onto the mouthpiece after each use (Figure M), to prevent contamination of the inhaler with dust or other materials. You should discard your inhaler if you lose the cap.
Figure M Additional information
What should you do if you accidently prepare a dose? Store your inhaler with the protective cap in place until it is time to inhale your medicine, then remove the cap and start at Step 1.6. How does the dose indicator work?
Red band
Figure N How do you know that your inhaler is empty? When the green button will not return to its full upper position and is locked in a middle position, you have reached the last dose (Figure O). Even though the green button is locked, your last dose may still be inhaled. After that, the inhaler cannot be used again and you should start using a new inhaler.
Locked
Figure O
How should you clean the inhaler? NEVER use water to clean the inhaler, as this may damage your medicine. If you wish to clean your inhaler, just wipe the outside of the mouthpiece with a dry tissue or paper towel.
Eklira Genuair 322 micrograms inhalation powder comes as inhaler containing 322mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Eklira Genuair 322 micrograms inhalation powder is aclidinium bromide.
This leaflet reproduces the patient information leaflet approved for Eklira Genuair 322 micrograms inhalation powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1).
Posology
The recommended dose is one inhalation of 322 micrograms aclidinium twice daily.
If a dose is missed the next dose should be taken as soon as possible. However, if it is nearly time for the next dose, the missed dose should be skipped.
Elderly
No dose adjustments are required for elderly patients (see section 5.2).
Renal impairment
No dose adjustments are required for patients with renal impairment (see section 5.2).
Hepatic impairment
No dose adjustments are required for patients with hepatic impairment (see section 5.2).
Paediatric population
There is no relevant use of Eklira Genuair in children and adolescents (under 18 years of age) for the indication of COPD.
Method of administration
For inhalation use.
Patients should be instructed on how to administer the product correctly as the Genuair inhaler may work differently from inhalers the patients may have used previously. It is important to instruct the patients to carefully read the Instructions for Use in the Package Leaflet, which is packed together with each inhaler.
For Instructions for Use, see section 6.6.
Hypersensitivity to aclidinium bromide or to the excipients listed in section 6.1.
Paradoxical bronchospasm:
Administration of Eklira Genuair may cause paradoxical bronchospasm. If this occurs, treatment with Eklira Genuair should be stopped and other treatments considered.
Deterioration of disease:
Aclidinium bromide is a maintenance bronchodilator and should not be used for the relief of acute episodes of bronchospasm, i.e. as a rescue therapy. In the event of a change in COPD intensity while the patient is being treated with aclidinium bromide so that the patient considers additional rescue medication is required, a re-evaluation of the patient and the patients' treatment regimen should be conducted.
Cardiovascular effects:
Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia were seen after the administration of Eklira Genuair (see section 4.8). Therefore, Eklira Genuair should be used with caution in patients with cardiac arrhythmias, a history of cardiac arrhythmias or with risk factors for cardiac arrhythmias.
Experience in patients with cardiovascular comorbidities in clinical trials is limited (see section 5.1). These conditions may be affected by the anticholinergic mechanism of action.
Anticholinergic activity:
Dry mouth, which has been observed with anticholinergic treatment, may in the long term be associated with dental caries.
Consistent with its anticholinergic activity, aclidinium bromide should be used with caution in patients with symptomatic prostatic hyperplasia or bladder-neck obstruction or with narrow-angle glaucoma (even though direct contact of the product with the eyes is very unlikely).
Excipients:
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Co-administration of aclidinium bromide with other anticholinergic-containing medicinal products has not been studied and is not recommended.
Although no formal in vivo drug interaction studies have been performed, inhaled aclidinium bromide has been used concomitantly with other COPD medicinal products including sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids without clinical evidence of drug interactions.
In vitro studies have shown that aclidinium bromide or the metabolites of aclidinium bromide at the therapeutic dose are not expected to cause interactions active substances that are substrates of P-glycoprotein (P-gp), or active substances metabolised by cytochrome P450 (CYP450) enzymes and esterases (see section 5.2).
Pregnancy
There are no data available on the use of aclidinium bromide in pregnant women.
Studies in animals have shown foetotoxicity only at dose levels much higher than the maximum human exposure to aclidinium bromide (see section 5.3). Aclidinium bromide should only be used during pregnancy if the expected benefits outweigh the potential risks.
Breast-feeding
It is unknown whether aclidinium bromide/metabolites are excreted in human milk. Animal studies have shown excretion of small amounts of aclidinium bromide/metabolites into milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Eklira Genuair therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility
Studies in rats have shown slight reductions in fertility only at dose levels much higher than the maximum human exposure to aclidinium bromide (see section 5.3). It is considered unlikely that aclidinium bromide administered at the recommended dose will affect fertility in humans.
Aclidinium bromide may have minor influence on the ability to drive and use machines. The occurrence of headache, dizziness or blurred vision following administration of aclidinium bromide (see section 4.8) may influence the ability to drive or to use machinery.
Summary of the safety profile
The most frequently reported adverse reactions with Eklira Genuair were headache (6.6%) and nasopharyngitis (5.5%).
Tabulated summary of adverse reactions
The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse reactions (i.e. events attributed to Eklira Genuair) observed with Eklira Genuair 322 µg (636 patients) in the pooled analysis of one 6-month and two 3-month randomised, placebo-controlled clinical trials or on post-marketing study results.
A placebo-controlled trial in 1791 patients with moderate to very severe COPD treated with Eklira Genuair up to 36 months did not identify other adverse reactions.
The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
System organ class
Preferred term
Frequency
Infections and infestations
Sinusitis
Common
Nasopharyngitis
Common
Immune system disorders
Hypersensitivity
Rare
Angioedema
Not known
Anaphylactic reaction
Not known
Nervous system disorders
Headache
Common
Dizziness
Uncommon
Eye disorders
Blurred vision
Uncommon
Cardiac disorders
Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia
Uncommon
Tachycardia
Uncommon
Palpitations
Uncommon
Respiratory, thoracic and mediastinal disorders
Cough
Common
Dysphonia
Uncommon
Gastrointestinal disorders
Diarrhoea
Common
Nausea
Common
Dry mouth
Uncommon
Stomatitis
Uncommon
Skin and subcutaneous tissue disorders
Rash
Uncommon
Pruritus
Uncommon
Renal and urinary disorders
Urinary retention
Uncommon
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
High doses of aclidinium bromide may lead to anticholinergic signs and symptoms.
However, single inhaled doses up to 6,000 µg aclidinium bromide have been administered to healthy subjects without systemic anticholinergic adverse reactions. Additionally, no clinically relevant adverse reactions were observed following 7-day twice daily dosing of up to 800 µg aclidinium bromide in healthy subjects.
Acute intoxication by inadvertent medicinal product ingestion of aclidinium bromide is unlikely, due to its low oral bioavailability and the breath-actuated dosing mechanism of the Genuair inhaler.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
⚠ Not the same combination. This medicine contains Aclidinium bromide. The products below do not contain exactly the same set of active substances — they are not direct substitutes.
Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Eklira Genuair 322 micrograms inhalation powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.